Jove
Visualize
Contact Us

Related Concept Videos

GPCRs Regulate Adenylyl Cylase Activity01:09

GPCRs Regulate Adenylyl Cylase Activity

5.9K
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
5.9K
Transducer Mechanism: G Protein–Coupled Receptors01:30

Transducer Mechanism: G Protein–Coupled Receptors

2.5K
G Protein–Coupled Receptors (GPCRs) are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to various stimuli. GPCRs regulate critical physiological pathways and are excellent drug targets for treating diseases such as diabetes, cancer, obesity, depression, or Alzheimer's. Nearly 35% of approved drugs implement their therapeutic effects by selectively interacting with specific GPCRs.
GPCRs are also called heptahelical,...
2.5K
G Protein-coupled Receptors01:15

G Protein-coupled Receptors

13.5K
G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
13.5K
Drug-Receptor Interaction: Agonist01:25

Drug-Receptor Interaction: Agonist

2.8K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
2.8K
GPCR Desensitization01:12

GPCR Desensitization

6.5K
G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...
6.5K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

7.5K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
7.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The GPCR Connection: Linking Alzheimer's Disease and Glioblastoma.

Journal of cellular and molecular medicine·2026
Same author

Artificial intelligence in rare diseases: toward clinical impact.

Trends in pharmacological sciences·2025
Same author

Exploring the biodegradation of PET in mangrove soil and its intermediates by enriched bacterial consortia.

Environmental technology·2025
Same author

Exploring the impact of the stargazin V143L mutation on the dynamics of the AMPA receptor: stargazin complex.

Frontiers in cellular neuroscience·2025
Same author

GPCR oligomerization across classes: A2AR-mediated regulation of mGlu5R activation.

International journal of biological macromolecules·2025
Same author

PFAS biodegradation by Labrys portucalensis F11: Evidence of chain shortening and identification of metabolites of PFOS, 6:2 FTS, and 5:3 FTCA.

The Science of the total environment·2025
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Sep 16, 2025

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators
07:41

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators

Published on: February 20, 2018

9.0K

GPCR-A17 MAAP: mapping modulators, agonists, and antagonists to predict the next bioactive target.

Ana B Caniceiro1,2,3,4, Ana M B Amorim1,2,3,4, Nícia Rosário-Ferreira1,2,3,4

  • 1CNC-UC - Center for Neuroscience and Cell Biology, University of Coimbra, Rua Larga, Ed FMUC, Piso 1, 3004-504, Coimbra, Portugal.

Journal of Cheminformatics
|July 11, 2025
PubMed
Summary

This study introduces the GPCR-A17 Modulator, Agonist, Antagonist Predictor (MAAP), an ensemble machine learning model for predicting G Protein-Coupled Receptor interactions. MAAP accelerates drug discovery by accurately identifying potential therapeutic agents for GPCR-A17 targets.

Keywords:
AgonistAntagonistBinding affinity (Ki)Drug discoveryEnsemble learningGPCR subfamily A17Modulator

More Related Videos

A Flow Cytometry-based Assay to Identify Compounds That Disrupt Binding of Fluorescently-labeled CXC Chemokine Ligand 12 to CXC Chemokine Receptor 4
06:56

A Flow Cytometry-based Assay to Identify Compounds That Disrupt Binding of Fluorescently-labeled CXC Chemokine Ligand 12 to CXC Chemokine Receptor 4

Published on: March 10, 2018

13.9K
Monitoring GPCR-β-arrestin1/2 Interactions in Real Time Living Systems to Accelerate Drug Discovery
08:21

Monitoring GPCR-β-arrestin1/2 Interactions in Real Time Living Systems to Accelerate Drug Discovery

Published on: June 28, 2019

7.0K

Related Experiment Videos

Last Updated: Sep 16, 2025

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators
07:41

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators

Published on: February 20, 2018

9.0K
A Flow Cytometry-based Assay to Identify Compounds That Disrupt Binding of Fluorescently-labeled CXC Chemokine Ligand 12 to CXC Chemokine Receptor 4
06:56

A Flow Cytometry-based Assay to Identify Compounds That Disrupt Binding of Fluorescently-labeled CXC Chemokine Ligand 12 to CXC Chemokine Receptor 4

Published on: March 10, 2018

13.9K
Monitoring GPCR-β-arrestin1/2 Interactions in Real Time Living Systems to Accelerate Drug Discovery
08:21

Monitoring GPCR-β-arrestin1/2 Interactions in Real Time Living Systems to Accelerate Drug Discovery

Published on: June 28, 2019

7.0K

Area of Science:

  • Pharmacology and Bioinformatics
  • Computational Drug Discovery

Background:

  • G Protein-Coupled Receptors (GPCRs) are crucial for cellular signaling and represent significant drug targets.
  • The GPCR-A17 subfamily is implicated in various diseases, necessitating novel therapeutic strategies.

Purpose of the Study:

  • To develop an advanced machine learning model for predicting the functional roles of agonists, antagonists, and modulators in GPCR-A17 interactions.
  • To accelerate the drug discovery process for GPCR-A17-related diseases.

Main Methods:

  • An ensemble machine learning model, GPCR-A17 Modulator, Agonist, Antagonist Predictor (MAAP), was developed.
  • MAAP integrates XGBoost, Random Forest, and LightGBM algorithms.
  • The model was trained on a dataset of over 3,000 ligands and 6,900 protein-ligand interactions from multiple databases.

Main Results:

  • The MAAP model demonstrated strong predictive performance with high F1 scores and AUC values on both testing and independent validation datasets.
  • A Ki-filtered subset of interactions further improved predictive accuracy.
  • Achieved F1 scores of 0.9179 (testing) and 0.7151 (independent validation), with AUCs of 0.9766 and 0.8591, respectively.

Conclusions:

  • GPCR-A17 MAAP effectively predicts ligand interactions, significantly aiding experimental validation.
  • The model accelerates the identification of potential drug candidates for GPCR-A17 targets.
  • The developed tool and data are publicly available on GitHub to support further research.